Kalust Ucar, M.D.
- Hematologic Oncology
- Medical Oncology
- Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
Kalust Ucar, M.D., is excited to offer his patients innovative cancer therapies that can improve their quality of life. He is inspired when patients who once needed a wheelchair can walk again. In 2007, Dr. Ucar received a Values in Action award from Glendale Memorial Hospital and Health Center for exhibiting dignity, collaboration, justice, stewardship and excellence in his cancer care.
Fluent in Armenian and Turkish, Dr. Ucar studied medicine at Istanbul University in Turkey. Moving to the U.S., he performed research at Roswell Park Comprehensive Cancer Center in New York and then joined SUNY as an intern, resident and fellow in endocrinology. Dr. Ucar specialized in oncology and hematology as a fellow at UCLA, where he was nominated for a teaching award and went on to become a faculty member.
His hobbies include reading, golfing and sailing.
Location
Glendale
Suite 100-B
Glendale, CA 91204
Education & Experience
1997, Diplomat, American Board of Medical Oncology: 118015
1996, Diplomat, American Board of Hematology: 118015
1988, Diplomat, American Board of Internal Medicine: 118015
1988, California State License: A 049259. New York State License: 174675
1986, FLEX, ID#:560131017, ECFMG, Standard Certificate: 334-240-9
1981, Doctor of Medicine, Istanbul University, Istanbul, Turkey
1975, Bachelor of Science, Robert College, Istanbul, Turkey
1994, Hematology-Oncology, University of California Los Angeles, Los Angeles, CA
1991, Endocrinology, University of Buffalo, Buffalo, NY
1988, Internal Medicine, University at Buffalo, Buffalo, NY
1986, Internal Medicine, University at Buffalo, Buffalo, NY
2021-present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Glendale, CA
1996-2021, Medical Oncologist, Pacific Shores Medical Group, Glendale and Long Beach (Elm), CA
Awards & Memberships
Awards
1991-92, 1992-93, Fellow Teaching Award Nomination, UCLA
1975-1981, Merit Scholarship, Istanbul University
1971-1975, Merit Scholarship, Robert College
1975, Ranked in top 1% in nation-wide university entrance examination
1982, Ranked in top 1% in field medicine examinations
Memberships
American College of Physicians
American Society of Hematology
American Society of Clinical Oncology
The Southwest Oncology group (SWOG)
Publications
- Raza A. Maheshwari Y, Ucar K. Mayers G, Preisler HD. Proliferative Characteristics of Acute Nonlymphocytic Leukemia in Vivo. Acta Haematologica (Basel), 77(3):140-145, 1987.
- Ucar K, Durmaz R. High Dose Chemotherapy Regimens. Medical Hypothesis, 19(2):101-102, 1986.
- Raza A, Ucar K, Preisler HD, Mayers G. In Vitro and in Vivo Assessment of Sensitivity to Ara-C in Myeloid Leukemias. Seminars in Oncology, 12(2) suppl 3(Jun):9-19, 1985.
- Raza A, Ucar K, Preisler HD. Double Labeling and In Vitro Versus in Vivo Incorporation of Bromodeoxyuridine in Patients with Acute Nonlymphocytic Leukemia. Cytometry, 6(6):633-640, Nov 1985.
- Raza A, Spiridonidis C, Ucar K, Mayers G, Bankert R, Preisler HD. Double Labeling of S-phase Murine Cells with Bromodeoxyuridine and a Second DNA Specific Probe. Cancer Research, 45(5):2283-2287, May 1985.
- Raza A, Ucar K, Preisler HD. In Vitro Labeling Index, 3Hara-C Incorporation and Inhibition of DNA Synthesis Versus Induction Outcome in AML Patients Treated with High Dose Ara-C. Excerpta Medica, 1985.
- Raza A, Bhayana R, Ucar K, Kirshner J, Preisler HD. Differences Between Labeling Index and DNA Histograms in Assessing S-phase Cells Form a Homogeneous Group of Chronic Phase CML Patients. Cytometry, 6(5):445- 451, September 1985.
- Raza A, Ucar K, Bhayana R, Kempski M, Preisler HD. Utility and Sensitivity for Anti-Brdu Antibodies in Assessing S-phase Cells Compared to Autoradiography. Cell Biochem Function, 3(2):149-153, April 1985.
- Ucar K. The effects of histamine H2 receptor antagonists on melanogenesis and cellular proliferation in melanoma cells in culture. Biochemical and Biophysical Research Communications, 177(1)”545050, 1991.
- Bick RL, Ucar K. Hypercoagulability and thrombosis. Hematology Oncology Clinic North Am, 6(6): 1421-1431, 1992.
- Philip R, Brunette E, Kilinski L, Murugesh D, McNally MA, Ucar K, Rosenblatt J, Okarma TB Lebkowski JS. Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes. Molec & Cellular Biol, 14(4):2411-2418, Apr 1994
- Ucar K, Seeger RC, Challita PM, Watanabe CT, Yen TL, Morgan JP, Amado R, Chou E, McCallister T, Barber JR, Joily DJ, Reynolds CP, Gangaballi Ri, Roseblatt JD. Sustained Cytokine Production and Immunophenotypic Changes in Human Neuroblastoma Cell Lines Transduced with a Human Gamma Interferon Vector. Cancer Gene Therapy, 2(3):171-181, 9/95.
- Ucar K, Figlin R. Principles of Immunotherapy of Cancer. In Current Cancer Diagnosis and Treatment, Henderson C, Wilson C, Phillips T, Debas H, Northfelt D (eds). Appleton and Lange, Norwalk, CT, in press.
- Ucar R, Sanwo M, Ucar K, Beall G. Interferons: their role in clinical practice. Annals of Allergy, Asthma, & Immunology, 75(5):377-386, 1995.